Management of patients with newly diagnosed malignant primary brain tumors with a focus on the evolving role of temozolomide

Therapeutics and Clinical Risk Management

Volumn 3, Issue 6, 2007, Pages 1027-1033

  Gilbert, Mark R ^a   Armstrong, Terri S ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

Author keywords

Glioblastoma; Glioma; MGMT; Patient management; Temozolomide

Indexed keywords

ANTICONVULSIVE AGENT; CORTICOSTEROID; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MEDICAL RESEARCH; METHYLATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROSURGERY; PATIENT CARE; PATIENT SAFETY; PATIENT SELECTION; PROGNOSIS; PROMOTER REGION; PROPHYLAXIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; REVIEW; SEIZURE; SURGICAL TECHNIQUE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 38049161075     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Athanassiou H, Synodinou M, Maragoudakis E, et al. 2005. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol, 23:2372-7.
2. CBTRUS. 2005. Statistical report: primary brain tumors in the United States, 1998-2002. Published by the Central Brain Tumor Registry of the United States.
3. Cohen MH, Johnson JR, Pazdur R. 2005. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res, 11:6767-71.
4. Combs SE, Gutwein S, Schulz-Ertner D, et al. 2005. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol, 181:372-7.
5. Curran WJ Jr, Scott CB, Horton J, et al. 1993. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst, 85:704-10.
6. Fetell MR, Grossman SA, Fisher JD, et al. 1997. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol, 15:3121-8.
7. Fine HA, Dear KB, Loeffler JS, et al. 1993. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 71:2585-97.
8. Gilbert MR, Friedman HS, Kuttesch JF, et al. 2002. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro-oncol, 4:261-7.
9. Glantz MJ, Cole BF, Forsyth PA, et al. 2000. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 54:1886-93.
10. Green SB, Byar DP, Walker MD, et al. 1983. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep, 67:121-32.
11. Hildebrand J, Lecaille C, Perennes J, et al. 2005. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology, 65:212-15.
12. Lacroix M, Abi-Said D, Fourney DR, et al. 2001. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg, 95:190-8.
13. Macdonald DR, Kiebert G, Prados M, et al. 2005. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Investigation, 23:138-44.
14. Marras LC, Geerts WH, Perry JR. 2000. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer, 89:640-6.
15. Mehta N, Silverberg W. 2005. Role of radiotherapy in the treatment of gliomas. Expert Rev Neurother, 5(6 Suppl):S51-61.
16. Moots PL. 1998. Pitfalls in the management of patients with malignant gliomas. Semin Neurol, 18:257-65.
17. [MRC] Medical Research Council Brain Tumor Working Party. 2001. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol, 19:509-18.
18. Newlands ES, Blackledge GR, Slack JA, et al. 1992. Phase I trial of temozolomide (CCRG 81045: M and B 39831: NSC 362856). Br J Cancer, 65:287-91.
19. O'Reilly SM, Newlands ES, Glaser MG, et al. 1993. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer, 29A:940-2.
20. Stewart LA. 2002. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 359:1011-18.
21. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. 2002. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol, 20:1375-82.
22. Tolcher AW, Gerson SL, Denis L, et al. 2003. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer, 88:1004-11.
23. Vick NA, Paleologos NA. 1995. External beam radiotherapy: hard facts and painful realities. J Neurooncol, 24:93-5.
24. Walker MD, Alexander E Jr, Hunt WE, et al. 1978. Evaluation of BCNU and/ or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 49:333-43.
25. Walker MD, Green SB, Byar DP, et al. 1980. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med, 303:1323-9.
26. Wen P, Toon TS, Black P. 2001. Clinical imaging, and laboratory diagnosis of brain tumors. In Laws E, Kaye A. Brain tumors. New York: Jones and Bartlett, p 24-50.
27. Wick W, Steinbach JP, Kuker WM, et al. 2004. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology, 62:2113-15.
28. Yung WK, Albright RE, Olson J, et al. 2000. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer, 83:588-93.
29. Yung WK, Prados MD, Yaya-Tur R, et al. 1999. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol, 17:2762-71.